Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change-Reference-Cited by-同舟云学术

Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change

Published:2020-04-21 Issue:5 Volume:26 Page:662-672
ISSN:1527-6465
Container-title:Liver Transplantation
language:en
Short-container-title:Liver Transpl

Author:

Brondfield Max N.¹^ORCID,Dodge Jennifer L.²,Hirose Ryutaro²,Heimbach Julie³,Yao Francis Y.²⁴,Mehta Neil⁴^ORCID

Affiliation:

1. Department of Medicine University of California, San Francisco San Francisco CA

2. Division of Transplant Surgery Department of Surgery University of California San Francisco CA

3. Division of Transplantation Department of Surgery Mayo Clinic Rochester MN

4. Division of Gastroenterology Department of Medicine University of California, San Francisco San Francisco CA

Publisher

Wiley

Subject

Transplantation,Hepatology,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lt.25701

Reference27 articles.

1. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy

2. Hepatocellular Carcinoma Patients Are Advantaged in the Current Liver Transplant Allocation System

3. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma

4. MELD Exceptions and Rates of Waiting List Outcomes

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous Risk Score Predicts Waitlist and Post-transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes;Clinical Gastroenterology and Hepatology;2024-06

2. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma;Transplantation;2023-12-13

3. Chasing equity: The evolving effects of MMaT-3 policy on outcomes of liver transplantation for hepatocellular carcinoma;Liver Transplantation;2023-05-30

4. Geographic disparities in access to liver transplantation;Liver Transplantation;2023-05-29

5. Would a 6-Month Wait Time for Patients With Hepatocellular Carcinoma Improve Organ Allocation in Centers With Active Living Related Liver Transplant Activity?;Experimental and Clinical Transplantation;2023-02